

Research Article

HPLC Quantification of Cytotoxic Compounds from *Aspergillus niger*

Paula Karina S. Uchoa, Leandro Bezerra de Lima, Antonia T. A. Pimenta, Maria da Conceição F. de Oliveira, Jair Mafezoli, and Mary Anne S. Lima

Departamento de Química Orgânica e Inorgânica, Centro de Ciências, Universidade Federal do Ceará, Fortaleza, CE, Brazil

Correspondence should be addressed to Mary Anne S. Lima; mary@dqoi.ufc.br

Received 5 December 2016; Revised 14 March 2017; Accepted 19 March 2017; Published 30 April 2017

Academic Editor: Marco Radi

Copyright © 2017 Paula Karina S. Uchoa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A high-performance liquid chromatography method was developed and validated for the quantification of the cytotoxic compounds produced by a marine strain of *Aspergillus niger*. The fungus was grown in malt peptone dextrose (MPD), potato dextrose yeast (PDY), and mannitol peptone yeast (MnPY) media during 7, 14, 21, and 28 days, and the natural products were identified by standard compounds. The validation parameters obtained were selectivity, linearity (coefficient of correlation > 0.99), precision (relative standard deviation below 5%), and accuracy (recovery > 96).

1. Introduction

Studies on marine-derived fungi as source of natural products have shown a sharp increase in recent years, due to the discovery of new molecular structures containing a broad of pharmacological property [1–5].

As part of an investigative effort to find promising anti-cancer agents from marine-derived fungi [6–8], the chemical investigation of a strain of *Aspergillus niger* (BRF074), recovered from sediments of the Northeast Brazilian coast, yielded the new furan ester derivative (**1**) and the cyclopeptides malformins A (**2**) and C (**3**) [9] (Figure 1).

Malformins are a group of cyclic pentapeptides with a disulfide bond formed from two cysteine thiols. These compounds show a variety of biological activities [10, 11] such as enhanced fibrinolytic activity [12] and antimalarial and antitrypanosomal properties [13]. The distinct activity profiles of the malformins A (**2**) and C (**3**) against cancer cell lines are also well reported in the literature [14–16]. These compounds have been found to be strongly cytotoxic against the human cancer cell lines NCI-H460 (non-small-cell lung carcinoma, IC_{50} 0.07 μ M), MIA Pa Ca-2 (pancreatic inducing root curvatures and malformations in plants [17, 18],

antibacterial activity cancer, IC_{50} 0.05 μ M), MCF-7 (breast cancer, IC_{50} 0.10 μ M), and SF-268 (CNS cancer; glioma, IC_{50} 0.07 μ M) with slight selectivity towards the pancreatic cancer cell line (MIA Pa Ca-2) compared with the normal human primary fibroblast cells WI-38 (IC_{50} 0.10 μ M) [16]. Compound **1**, a furan ester derivative, showed cytotoxic activity against HCT-116 tumor cell line with IC_{50} 2.9 μ M [9].

The production of the cytotoxic compounds **1–3** by *A. niger* (BRF 074), cultured under different growth conditions, was investigated and quantified through high-performance liquid chromatography (HPLC) method using a diode array detector (DAD).

2. Experimental

2.1. Samples, Chemicals, and Materials. The furan ester derivative (**1**) and malformins A (**2**) and C (**3**) used for the preparation of standard solutions were isolated from the marine-derived fungus *Aspergillus niger* (BRF 074) as previously described [9]. HPLC-grade acetonitrile and methanol were purchased from Tedia®. All other chemicals were of analytical-grade in the highest purity available. Water was distilled and purified using a Millipore Milli Q Plus system




FIGURE 1: Cytotoxic compounds 1–3 produced by *Aspergillus niger* (BRF074).

(Bedford, USA). The nutrient media used in this work, malt peptone dextrose, MPD, potato dextrose yeast, PDY, and mannitol peptone yeast, MnPY, were obtained from Himedia® Laboratories.

2.2. Fungal Strain. The fungal strain of *A. niger* (BRF 074) was recovered from sediments collected by autonomous diving in the vicinities of Pecém's offshore port terminal (3°32'27" S; 38°47'58" W), state of Ceará, Northeast of Brazil, and its isolation and identification was performed as previously reported [8, 9].

2.3. Cultivation of *A. niger* (BRF 074) and Extract Preparation. The strain of *A. niger* (BRF 074) was previously grown in potato dextrose agar (PDA) in reconstructed sea water. Agar pieces with 5 mm diameter of 7-day-old cultures were used as precultures and transferred to a 250 mL Erlenmeyer flask with 100 mL of the nutrient medium: malt peptone dextrose, MPD (malt, 20.0 g L⁻¹; peptone, 2.0 g L⁻¹; dextrose, 20.0 g L⁻¹), potato dextrose yeast, PDY (potato dextrose yeast, 24.0 g L⁻¹; yeast, 3.0 g L⁻¹), or mannitol peptone yeast, MnPY (mannitol, 4.0 g L⁻¹; peptone, 2.0 g L⁻¹; yeast, 2.0 g L⁻¹).

The fungal strain was grown under static conditions at room temperature (28°C) during 7, 14, 21, and 28 days. The culture broths were separated from mycelium by filtration and submitted to partition with EtOAc (3 × 30 mL) to afford the crude extracts (MPD, PDY, and MnPY) after solvent distillation.

2.4. Quantitative High-Performance Liquid Chromatography Analysis (HPLC Analysis). Samples were filtered through a 0.45 μm Millex-HV PVDF membrane (Millipore, New Bedford, MA, USA). HPLC analyses were performed on a Shimadzu chromatographer equipped with a ternary pump (Shimadzu LC-20AT) and DAD detector (Diode Array Detector) (Shimadzu SPD-M20A, Kyoto, Japan) and carried out on an analytical column (Phenomenex® ODS 100 A 250 mm × 4.60 mm, 5 μm) preceded by an C18 guard column (2.0 cm × 4.0 mm; 5 μm), also from Phenomenex. LC solutions software (version 1.25) was used for data processing. Chromatographic conditions were gradient using acetonitrile and water as mobile phase, initially consisting of acetonitrile/water (2 : 8

v/v) and increasing up to acetonitrile/water (8 : 2 v/v) in 30 minutes at a flow rate of 1 mL·min⁻¹. The mobile phase was prepared daily and degassed by sonication before use. The column temperature was 25°C and the injection volume was 20 μL. The UV spectra were monitored over a range of 450 to 200 nm, while the chromatograms were recorded at 273 nm to detect the furan ester derivative (1), and to detect malformins A (2) and C (3) the PAD detector was set at λ = 203 nm.

Methanol was used to prepare all standard solutions and extracts. The standard solutions were used in six different concentrations, as follows: 12.5, 25.0, 100.0, 150.0, 250.0, and 500.0 μg·mL⁻¹, and the concentration of the solution extracts was 2,000 μg·mL⁻¹.

2.5. Analytical Method Validation. The validation of the analytical method was performed in the HPLC-DAD system and the validated parameters evaluated were specificity, linearity, accuracy, precision (repeatability and intermediate precision), limit of quantification (LOQ), and limit of detection (LOD), which are in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines [19].

The linearity was determined by the correlation coefficients of the analytical curves, which were built by analyzing the working solutions at six different concentrations. The method linearity for the three compounds was tested through linear least-square regression analysis based on calibration curves constructed by using 12.5, 25.0, 100.0, 150.0, 250.0, and 500.0 μg·mL⁻¹ solutions (Graphpad Prism® 5.03 software).

The limits of detection (LOD) and quantification (LOQ) were calculated based on the standard deviation and slope of the regression curves.

The precision was evaluated in two steps: repeatability and intermediate precision. The repeatability was determined by injecting in triplicate, on the same day, standard solutions at three different concentrations (25.0, 100.0, and 500.0 μg mL⁻¹). Intermediate precision was estimated by analyzing, in triplicate, the same solutions employed in the repeatability test on three consecutive days. The results obtained were expressed in terms of relative standard deviation (RSD).

TABLE 1: Parameters of the analytical curves utilized for quantification of the bioactive compounds 1–3 produced by *A. niger* (BRF 074).

Compound	Linearity range ($\mu\text{g mL}^{-1}$)	Regression equation ^a	Correlation factor (r^2)
Furan ester (1)	12.5–500.0	$y = 11717.0x - 136817.5$	0.9984
Malformin A (2)	12.5–500.0	$y = 26362.2x - 246504.3$	0.9996
Malformin C (3)	12.5–500.0	$y = 26160.0x - 246504.3$	0.9991

^aSix data points ($n = 3$).TABLE 2: Repeatability and intermediate precision data of the bioactive compounds 1–3 produced by *A. niger* (BRF 074).

Compound	Concentration ($\mu\text{g mL}^{-1}$)	Repeatability ($n = 3$)			Intermediate precision ($n = 3$)			
		Measured values ($\mu\text{g mL}^{-1}$)	Mean ($\mu\text{g mL}^{-1}$)	RSD (%)	Concentration ($\mu\text{g mL}^{-1}$)	Measured values ($\mu\text{g mL}^{-1}$)	Mean ($\mu\text{g mL}^{-1}$)	RSD (%)
Furan ester (1)	50.0	54.2892	54.3067	0.06	50.0	50.1338	50.1595	0.17
		54.3437				50.2537		
		54.2872				50.0912		
	250.0	233.8591	234.1195	0.11	250.0	245.7478	245.7319	0.01
		234.3952				245.7127		
		234.1043				245.7350		
500.0	509.2980	509.2795	0.01	500.0	500.9200	501.0567	0.06	
	509.2856				500.8662			
	509.2549				501.3840			
Malformin A (2)	50.0	51.7388	51.6893	0.14	50.0	49.3617	49.3967	0.06
		51.7246				49.4094		
		51.6044				49.4188		
	250.0	246.2154	246.1638	0.03	250.0	239.8196	239.9550	0.05
		246.0825				240.0045		
		246.1936				240.0410		
500.0	503.6637	503.2790	0.07	500.0	505.5801	505.6792	0.02	
	502.9370				505.6485			
	503.2363				505.8089			
Malformin C (3)	50.0	52.8589	52.8315	0.06	50.0	51.1270	51.0618	0.17
		52.7992				51.0972		
		52.8364				50.9613		
	250.0	241.1501	241.3161	0.06	250.0	231.0606	231.1973	0.06
		241.3867				231.2140		
		241.4114				231.3173		
500.0	505.8446	505.9971	0.18	500.0	510.3529	510.2467	0.02	
	506.9641				510.2716			
	505.1826				510.1154			

The accuracy was determined from recovery tests with solutions of the standard compounds having low, medium, and high concentration levels, and the recoveries of the three standard compounds were calculated from the corresponding calibration curve according to the following equation:

$$\text{Recovery (\%)} = \left(\frac{\text{amount found}}{\text{amount added}} \right) \times 100. \quad (1)$$

The test concentrations used were 140.0, 186.0, and 233.0 $\mu\text{g mL}^{-1}$ for the furan ester derivative (1); 70.0, 92.0, and 115.0 $\mu\text{g mL}^{-1}$ for malformin A (2); and 101.0, 134.0, and 166.0 $\mu\text{g mL}^{-1}$ for malformin C (3). All the samples were analyzed in quintuplicate.

Accuracy was expressed as the percentage of deviation between the measured value and the reference value.

The selectivity of the method was evaluated by analyzing sterile medium (blank) and fungal culture broth under the conditions previously established.

2.6. Quantification and Validation Procedures. To ensure the linearity, calibration curves of the three compounds were obtained. Standard solutions of the furan ester derivative (1) and malformins A (2) and C (3) were prepared at a concentration range of 12.5 to 500.0 $\mu\text{g mL}^{-1}$. All the curves showed a linear response with $r^2 > 0.998$ in the selected range for each sample (Table 1).

The furan ester derivative (1) showed LOD of 46.0 $\mu\text{g mL}^{-1}$ and LOQ of 67.9 $\mu\text{g mL}^{-1}$. Malformin A (2) showed LOD of 22.7 $\mu\text{g mL}^{-1}$ and LOQ of 33.6 $\mu\text{g mL}^{-1}$, while malformin C (3) showed LOD of 34.7 $\mu\text{g mL}^{-1}$ and LOQ of 51.3 $\mu\text{g mL}^{-1}$.

The precision was estimated by measuring repeatability (intraday assay) and intermediate precision (interday assay), both in triplicate. All the values of relative standard deviation (RSD) in the repeatability and intermediate precision estimates were below 5% (Table 2), which did not exceed the limits recommended in the literature [19, 20].

TABLE 3: Accuracy data of the bioactive compounds 1–3 produced by *A. niger* (BRF 074).

Compound	Concentration ($\mu\text{g mL}^{-1}$)	Accuracy ($n = 5$)		Recovery (%)
		Measured values ($\mu\text{g mL}^{-1}$)	Mean ($\mu\text{g mL}^{-1}$)	
Furan ester (1)	140.0	134.1553	134.0627	95.8
		133.9125		
		134.1571		
		134.2570		
		133.8316		
	186.0	178.5342	178.5453	95.9
		178.6454		
		178.5064		
		178.4201		
232.0	178.6202	223.9634	96.4	
	224.0426			
	223.6944			
	223.9213			
	224.0262			
Malformin A (2)	70.0	224.1322	72.9632	104.2
		72.7681		
		73.0678		
		73.0619		
		72.9432		
	92.0	72.9750	97.9246	106.4
		98.0389		
		97.8777		
		97.9863		
	115.0	97.9622	117.6743	102.3
		97.7580		
		117.8192		
117.5671				
117.6607				
Malformin C (3)	101.0	117.7728	102.5837	101.5
		117.5518		
		102.5096		
		102.4978		
		102.7050		
	134.0	102.5853	130.5013	97.4
		102.6210		
		130.4046		
		130.5980		
166.0	130.5686	160.6178	96.8	
	130.6417			
	130.2936			
	160.7364			
	160.7337			
	160.5222			
	160.4871			
	160.6094			

The accuracy of the method was evaluated by recovery experiments with the standard solutions at three different concentration levels. The recovery values ranged from 95.8 to 106.4% (Table 3) and were also in line with ICH parameters.

2.7. Method Application: Growth Behavior of *Aspergillus niger* (BRF 074). The method developed showed being efficient for

the quantitative analyses of three bioactive compounds produced by *A. niger* (BRF 074) in three fermentative mediums: malt peptone dextrose (MPD), potato dextrose yeast (PDY), and mannitol peptone yeast (MnPY).

These analyses were carried out after inoculation of the mycelia obtained from seed medium into MPD, PDY, and MnPY. In order to evaluate the kinetic production of the compounds, different periods of incubation were analyzed




FIGURE 2: HPLC chromatograms of the (a) standard compounds 1–3, (b) extract obtained from *A. niger* (BRF 074) cultured during 28 days in MPD medium, (c) extract obtained from *A. niger* (BRF 074) cultured during 28 days in PDY medium, and (d) extract obtained from *A. niger* (BRF 074) cultured during 28 days in MnPY medium. Chromatography conditions: reversed-phase column ODS (250 × 4.6 mm, 5 μm); gradient elution going from H₂O/MeCN 80 : 20 to H₂O/MeCN 20 : 80 in 30 minutes; flow rate of 1.0 mL min⁻¹; sample concentration of 2.0 μg mL⁻¹.

(7, 14, 21, and 28 days), and their concentrations in each period were obtained in triplicate ($n = 3$). The contents of the three cytotoxic compounds in the crude extracts, MPD and PDY, are shown in Table 4.

3. Results and Discussion

The focus of the study was to quantify the amount of the cytotoxic metabolites, furan ester derivative (1), and malformins A (2) and C (3), produced by the marine-derived strain of *A. niger* (BRF 074) grown in varied nutrient medium and time of cultivation.

The validation method was carried out simultaneously for the bioactive compounds, and the retention time was found

to be 13.7 min for 1 and 21.4 min and 22.1 min for 2 and 3, respectively. Although the analysis showed a relative long run time (30 min), the secondary metabolites could be analyzed with good separation and baseline resolution between all peaks (Figure 2).

The chromatographic analysis of the organic extracts (MPD, PDY, and MnPY) revealed a similar HPLC profile for MPD and PDY and suggested that the bioactive compounds were produced by *A. niger* in both culture media. No significant amounts of the analyzed compounds 1–3 were found in the extract from the MnPY medium.

In our analysis, the highest content (274.0 μg mL⁻¹) of 1 was found when using MPD as culture medium, during a growth period of 28 days. In this same condition, the contents

TABLE 4: Contents of the bioactive compounds 1–3 in MPD and PDY extracts produced by *A. niger* (BRF 074). Concentration of the extracts = 2,000 $\mu\text{g mL}^{-1}$.

Growth time (days)	Furan ester (1) (Rt = 13.7 min)	Malformin A (2) (Rt = 21.4 min)	Malformin C (3) (Rt = 22.1 min)
MPD extracts			
07	14.7	37.5	60.1
14	17.0	26.5	34.9
21	92.3	46.2	67.5
28	274.0	86.3	125.9
PDY extracts			
07	13.8	37.4	50.1
14	24.8	112.7	166.7
21	44.4	179.0	233.8
28	74.3	163.1	235.4

Concentration expressed as $\mu\text{g mL}^{-1}$ ($n = 3$).

of 2 and 3 were 86.3 $\mu\text{g mL}^{-1}$ and 125.9 $\mu\text{g mL}^{-1}$, respectively. On the other hand, the best condition for the production of 2 and 3 was achieved when using PDY as culture medium, within 21 and 28 days of growth. Within 21 days of growth, the concentrations of 2 and 3 were 179.0 and 233.8 $\mu\text{g mL}^{-1}$, respectively, while the concentration of 1 was 44.4 $\mu\text{g mL}^{-1}$. With 28 days of fermentation, also in the PDY medium, the concentrations of 2 and 3 did not change considerably when compared with 21 days of growth, and their respective contents were 163.1 and 235.4 $\mu\text{g mL}^{-1}$. However, the concentration of 1 increased almost twice (74.3 $\mu\text{g mL}^{-1}$) when comparing the periods of 28 and 21 days of fermentation.

The developed chromatographic method herein described proved to be efficient in the quantitative analyses of the cytotoxic compounds 1–3 in the extracts from *A. niger* cultured under different conditions, as confirmed by its validated analytical parameters by HPLC-PDA system. Considering these aspects, the analytical quantitative method can be a useful and important tool for monitoring the production of the analyzed cytotoxic compounds by *A. niger*.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors acknowledge the Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico (FUNCAP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Coordenação de Aperfeiçoamento de Ensino Superior (CAPES) for the fellowships and financial support.

References

- [1] B. S. Davidson, "New dimensions in natural products research: cultured marine microorganisms," *Current Opinion in Biotechnology*, vol. 6, no. 3, pp. 284–291, 1995.
- [2] C. Bailly, "Ready for a comeback of natural products in oncology," *Biochemical Pharmacology*, vol. 77, no. 9, pp. 1447–1457, 2009.
- [3] J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro, and M. R. Prinsep, "Marine natural products," *Natural Product Reports*, vol. 31, no. 2, pp. 160–258, 2014.
- [4] C.-C. Chang, W.-C. Chen, T.-F. Ho, H.-S. Wu, and Y.-H. Wei, "Development of natural anti-tumor drugs by microorganisms," *Journal of Bioscience and Bioengineering*, vol. 111, no. 5, pp. 501–511, 2011.
- [5] W. H. Gerwick and B. S. Moore, "Lessons from the past and charting the future of marine natural products drug discovery and chemical biology," *Chemistry and Biology*, vol. 19, no. 1, pp. 85–98, 2012.
- [6] T. G. C. Montenegro, F. A. R. Rodrigues, P. C. Jimenez et al., "Cytotoxic activity of fungal strains isolated from the ascidian eudistoma vancouveri," *Chemistry and Biodiversity*, vol. 9, no. 10, pp. 2203–2209, 2012.
- [7] N. N. Saraiva, B. S. F. Rodrigues, P. C. Jimenez et al., "Cytotoxic compounds from the marine-derived fungus *Aspergillus* sp. recovered from the sediments of the Brazilian coast," *Natural Product Research*, vol. 29, no. 16, pp. 1545–1550, 2015.
- [8] B. S. F. Rodrigues, B. D. B. Sahn, P. C. Jimenez et al., "Bioprospection of cytotoxic compounds in fungal strains recovered from sediments of the Brazilian coast," *Chemistry and Biodiversity*, vol. 12, no. 3, pp. 432–442, 2015.
- [9] P. K. Uchoa, A. T. Pimenta, R. Braz-Filho et al., "New cytotoxic furan from the marine sediment-derived fungi *Aspergillus niger*," *Natural Product Research*, pp. 1–5, 2017.
- [10] S. Suda and R. W. Curtis, "Antibiotic properties of malformin," *Applied Microbiology*, vol. 14, no. 3, pp. 475–476, 1966.
- [11] B. Kobbé, M. Cushman, G. N. Wogan, and A. L. Demain, "Production and antibacterial activity of malforming C, a toxic metabolite of *Aspergillus niger*," *Applied and Environmental Microbiology*, vol. 33, no. 4, pp. 996–997, 1977.
- [12] Y. Koizumi and K. Hasumi, "Enhancement of fibrinolytic activity of U937 cells by malformin A1," *Journal of Antibiotics*, vol. 55, no. 1, pp. 78–82, 2002.
- [13] Y. Kojima, T. Sunazuka, K. Nagai et al., "Solid-phase synthesis and biological activity of malformin C and its derivatives," *Journal of Antibiotics*, vol. 62, no. 12, pp. 681–686, 2009.

- [14] K. Hagimori, T. Fukuda, Y. Hasegawa, S. Omura, and H. Tomoda, "Fungal malformins inhibit bleomycin-induced G2 checkpoint in Jurkat cells," *Biological and Pharmaceutical Bulletin*, vol. 30, no. 8, pp. 1379–1383, 2007.
- [15] M. Varoglu and P. Crews, "Biosynthetically diverse compounds from a saltwater culture of sponge-derived *Aspergillus niger*," *Journal of Natural Products*, vol. 63, no. 1, pp. 41–43, 2000.
- [16] J. Zhan, G. M. K. B. Gunaherath, E. M. K. Wijeratne, and A. A. L. Gunatilaka, "Asperpyrone D and other metabolites of the plant-associated fungal strain *Aspergillus tubingensis*," *Phytochemistry*, vol. 68, no. 3, pp. 368–372, 2007.
- [17] R. W. Curtis, "Curvatures and malformations in bean plants caused by culture filtrate of *Aspergillus niger*," *Plant Physiology*, vol. 33, no. 1, pp. 17–22, 1958.
- [18] R. W. Curtis, "Root curvatures induced by culture filtrates of *Aspergillus niger*," *Science*, vol. 128, no. 3325, pp. 661–662, 1958.
- [19] ICH, "Validation of analytical procedures: text and methodology—Q2(R1)," in *Proceedings of the International Conference on Harmonization (ICH '05)*, London, UK, 2005.
- [20] Q. B. Cass and A. L. G. Degani, *Desenvolvimento de Métodos por HPLC: Fundamentos, Estratégias e Validação*, UFSCar, São Carlos, Brazil, 2001.

